| Single-and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MM MS Truger, J Duell, X Zhou, L Heimeshoff, A Ruckdeschel, M John, ... Blood advances 5 (19), 3794-3798, 2021 | 62 | 2021 |
| Th17. 1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma AM Leipold, RA Werner, J Düll, P Jung, M John, E Stanojkovska, X Zhou, ... Leukemia 37 (3), 650-658, 2023 | 24 | 2023 |
| Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma M John, M Helal, J Duell, G Mattavelli, E Stanojkovska, N Afrin, ... Blood 144 (20), 2121-2135, 2024 | 11 | 2024 |
| RNA inhibits dMi-2/CHD4 chromatin binding and nucleosome remodeling I Ullah, C Thoelken, Y Zhong, M John, O Rossbach, J Lenz, M Gößringer, ... Cell reports 39 (9), 2022 | 8 | 2022 |
| PAF1c links S-phase progression to immune evasion and MYC function in pancreatic carcinoma A Gaballa, A Gebhardt-Wolf, B Krenz, G Mattavelli, M John, G Cossa, ... Nature Communications 15 (1), 1446, 2024 | 6 | 2024 |
| The impact of treatment-free intervals on T-cell exhaustion and clonotypic diversity in myeloma patients treated with BCMA bispecific antibodies F Eisele, N Afrin, E Stanojkovska, M John, M Helal, L Grundheber, P Weis, ... Blood 142, 1938, 2023 | 6 | 2023 |
| Changes in T‐cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T‐cell therapy in relapsed/refractory multiple … X Zhou, V Wagner, L Scheller, E Stanojkovska, C Riedhammer, X Xiao, ... British Journal of Haematology 205 (3), 999-1010, 2024 | 2 | 2024 |
| Prolonged Cytopenia following CAR T-Cell therapy in Relapsed/Refractory multiple myeloma: a prospective Comprehensive Biomarker Study X Zhou, V Wagner, E Stanojkovska, C Riedhammer, X Xiao, M John, ... Blood 142, 95, 2023 | 1 | 2023 |
| Pseudoprogression and Sarcoidosis-like Phenomena after CART-Cells and Bispecific Antibodies in Multiple Myeloma A Leipold, R Werner, J Duell, P Jung, M John, E Stanojkovska, X Zhou, ... Blood 140 (Supplement 1), 10020-10021, 2022 | 1 | 2022 |
| Combining SKY92 gene expression profiling and FISH (according to R2‐ISS) defines ultra‐high‐risk Multiple Myeloma X Zhou, A Hofmann, B Engel, C Vogt, S Nerreter, Y Tamamushi, F Schmitt, ... HemaSphere 9 (1), e70078, 2025 | | 2025 |
| Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma X Zhou, S Wiethe, A Wolff, MJ Steinhardt, N Afrin, M John, C Riedhammer, ... Blood 144, 4705, 2024 | | 2024 |
| Metabolic transformation by multiple myeloma cells renders immune cells dysfunctional L Grundheber, M John, N Afrin, M Helal, E Stanojkovska, J Mersi, ... Oncology Research and Treatment 46, 312-313, 2023 | | 2023 |
| P-489 Prolonged cytopenia after CAR T-cell therapy in multiple myeloma: results from a prospective comprehensive biomarker study X Zhou, E Stanojkovska, V Wagner, C Riedhammer, X Xiao, M John, ... Clinical Lymphoma Myeloma and Leukemia 23, S309, 2023 | | 2023 |
| Spatial Transcriptomics Reveals a Multi Cellular Ecosystem in Extramedullary Multiple Myeloma M Helal, M John, E Stanojkovska, G Mattavelli, L Grundheber, A Leipold, ... Blood 140 (Supplement 1), 7060-7061, 2022 | | 2022 |
| The T-Cell Metabolic Phenotype Is Dependent on Risk Status and Degree of PC Bone Marrow Infiltration in Multiple Myeloma M John, M Helal, L Grundheber, G Mattavelli, N Afrin, X Zhou, B Engel, ... Blood 140 (Supplement 1), 9959-9960, 2022 | | 2022 |
